TuisAMLX • NASDAQ
add
Amylyx Pharmaceuticals Inc
Vorige sluiting
$5,52
Dagwisseling
$5,33 - $5,55
Jaarwisseling
$1,58 - $7,26
Markkapitalisasie
492,06 m USD
Gemiddelde volume
1,03 m
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
NASDAQ
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Inkomste | — | — |
Bedryfskoste | 15,68 m | -72,85% |
Netto inkomste | -35,91 m | 69,77% |
Netto winsgrens | — | — |
Wins per aandeel | -0,42 | -242,05% |
EBITDA | -37,65 m | 69,09% |
Effektiewe belastingkoers | — | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 204,07 m | -45,33% |
Totale bates | 219,68 m | -47,38% |
Totale aanspreeklikheid | 18,26 m | -80,37% |
Totale ekwiteit | 201,42 m | — |
Uitstaande aandele | 89,14 m | — |
Prys om te bespreek | 2,44 | — |
Opbrengs op bates | -45,73% | — |
Opbrengs op kapitaal | -51,15% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | -35,91 m | 69,77% |
Kontant van bedrywe | -39,82 m | -8 043,97% |
Kontant van beleggings | -43,66 m | -5 430,77% |
Kontant van finansiering | 65,66 m | 50 023,66% |
Netto kontantverandering | -17,62 m | -5 121,08% |
Beskikbare kontantvloei | -25,80 m | -4 555,82% |
Meer oor
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024. Wikipedia
Gestig
2013
Webwerf
Werknemers
123
